Invests in
Locations:
Min Investment:
$100,000.00Max Investment:
$5,000,000.00Target Investment:
$1,500,000.00
Skills
Education
- EZ
- Uo
Lists including Marco
Investments
Orbis Medicines
Total Funding: $28M
Calluna Pharma
Total Funding: $81M
Inversago Pharma
Total Funding: $110M
NorthSea Therapeutics
Total Funding: $150M
Rectify Pharmaceuticals
Total Funding: $100M
Inflazome
Total Funding: $46M
Milestone Pharmaceuticals
Total Funding: $290M
Escalier Biosciences
Total Funding: $19M
Exosome Diagnostics
Total Funding: $110M
Prexton Therapeutics
Total Funding: $41M
Work Experience
2007
General Partner
2017
Partner
2014 - 2017
Principal
2010 - 2014
Senior Analyst
2007 - 2010
2024
Board Director at Calluna Pharma
2024
2021
Board Director at Sitala
2021
2021
Board Director at Rectify Pharma
2021
2020
Board Director at VectorY
2021
VectorY develops innovative vectorized antibody gene therapies
Chief Executive Officer
2020 - 2021
VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a special focus on muscle diseases.
2020 - 2023
Chairman of the Board
2020 - 2023
Oxitope Pharma was merged with Arxx Therapeutics into Calluna Pharma
2017 - 2023
Board Director at enGene
2017 - 2023
EnGene (Nasdaq: ENGN) develops non-viral gene therapies targeting mucosal tissues. Lead program is in pivotal clinical studies in NMIBC
2020 - 2023
Board Director at Inversago
2020 - 2023
Inversago develops peripherally acting CB1 inhibitors for treatment of metabolic and inflammatory diseases. Inversago was acquired by Novo Nordisk
2018 - 2023
Board Director at Escalier Biosciences
2018 - 2023
Escalier develops novel therapeutics to treat autoimmune diseases
2018 - 2020
Board Director at Inflazome
2018 - 2020
Inflazome was acquired by Roche